^
Association details:
| Biomarker: | IL10 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
T cell immune activation influences CDK4/6 inhibitors treatment response in metastatic breast cancer.
Published date:
05/28/2021
Excerpt:
Blood samples from MBC patients (p) treated with CDK4/6i were collected before treatment initiation...P stratification by treatment identified a cluster of cytokines differently expressed in palbociclib-treated p. Interestingly, basal IL-10 expression was significantly higher in the bad-responders group (p = 0.045)...
